Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of BNT162b2 COVID-19 mRNA vaccine in healthy adults in China
ChiCTR2000040044Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial Center for Disease Prevention and Control
- Start
- Nov 2020
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing BNT162b2 with Placebo (2 arms). Primary endpoints: Seroconversion rate of SARS-CoV-2 serum neutralizing titers and Geometric mean titer of SARS-CoV-2 serum neutralizing titers. Planned start Nov 2020; status: not yet recruiting.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2000040044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040044.